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In spite of major advances in screening, surgery, radiation therapy, endocrine and chemo-
therapy (CT) for patients with early-stage breast cancer (BC), there has been only a modest
progress in improving survival for women with metastases. Almost all MBC patients are
ultimately candidates for systemic therapy, either hormonal or CT. The choice of therapy
depends on the disease free interval from the end of adjuvant therapy, whether or not
the patient is symptomatic and, if so, the severity these symptoms; and whether the
tumour is hormone receptor positive or negative. Standard first-line chemotherapy con-
sists of anthracyclines plus or minus a taxane depending on the end point of treatment.
A recently published individual patient’s data metanalysis confirms this concept. Tax-
ane-based combinations were significantly better than A-based combinations in terms of
response rate (RR) and progression free survival, but not in terms of survival. Polichemo-
therapy remain indicated if the end point is citoreduction of high tumour burden. Single
agent taxane and single agent A are equivalent in term of RR and overall survival (OS)
and are prescribed if the end point is the control of disease and prolongation of survival.
First line aromatase inhibitors (steroidal or non-steroidal) and subsequent fulvestrant or
an AI of the opposite class is an appropriate sequence for the treatment of advanced endo-
crine responsive disease. The benefit of an angiogenetic therapy with the scope of blocking
certain critical pathways for tumoural cells (for example angiogenesis), has recently been
confirmed in at least 2 phase III trials comparing CTwith or without bevacizumab. The near
future will tell us if a new scenario will become standard in clinical practice.
 2008 Elsevier Ltd. All rights reserved.1. Introduction end of adjuvant therapy, whether or not the patient isIn spite of major advances in screening, surgery, radiation
therapy, endocrine therapy and chemotherapy (CT) for pa-
tients with early-stage breast cancer (BC), there has been
only a modest progress in improving survival for women
with metastases. The median survival for metastatic
breast cancer (MBC) patients remains 18–24 months. Al-
most all MBC patients are ultimately candidates for sys-
temic therapy, either hormonal or CT. The choice of
therapy depends on the disease-free interval from theer Ltd. All rights reserved
; fax: +39 0363424380.
eviglio.bg.it (S. Barni).symptomatic and, if so, the severity these symptoms;
and whether the tumour is hormone receptor positive or
negative. Despite treatment approaches such as target
and hormone therapy for BC, CT remains an important
component for the treatment of most BCs. Target agents
and/or hormone agents are often combined with CT to
improve the results, whilst CT as a single agent or in
combination with other agents remains the cornerstone
of therapy for HER2-neu negative, hormone receptor-nega-
tive patients..
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receptor (PR)-positive tumours are more likely to develop
bone metastases, those with ER- and PR-negative tumours
are more likely to develop liver and other visceral metastasis,
whereas in the so-called triple negative phenotype there is a
higher incidence of developing brain metastases rather than
bone or lungmetastases. In spite of these biologic differences,
all sites of metastatic disease in patients with ER- or PR-posi-
tive tumours are potentially responsive to endocrine therapy.
For patients with ER- and PR-negative disease who have
slowly progressive metastases, minimal symptoms, single
site of recurrence or advanced age, a single agent CT could
be offered. Conversely, because the overall response rate
(RR) to CT is higher than that to endocrine therapy, patients
with rapidly progressive tumours, younger age or important
tumour-related symptoms should be considered for combina-
tion CT. A common concern is whether patients with hor-
mone receptor-positive tumours and symptomatic, rapidly
progressing metastatic disease should be considered for a
combined modality treatment with CT and subsequently
maintenance endocrine therapy. Clinical trials comparing
CT alone with CT plus endocrine therapy have occasionally
shown a higher RR but no survival advantage for combined
treatment.1 Moreover, there is a theoretical concern that com-
bined modality treatment might be antagonistic.
The goals of systemic therapy in the metastatic setting are
prolongation of disease control, maintenance or improve-
ment in the quality of life and above all to prolong survival.
Although achieving an objective response is highly gratifying
for both patients and physicians, stabilising metastases is
also a desirable treatment goal, especially for patients who
are minimally symptomatic. Patients with stable metastases
for 24 weeks or longer have survival similar to that of patients
with complete and partial responses2; indeed, it is now com-
mon in clinical trials to report the so-called ‘clinical benefit
response’, which includes the percentage of patients with sta-
ble disease for 24 weeks or more in addition to the percentage
with complete and partial responses.
In this review we shall summarise the treatment strategy
of endocrine responsive and hormonal receptor-negative ad-
vanced disease. The paradigm of HER2-neu positive MBC will
be the object of a specific article.2. CT for HER-2 negative advanced BC
CT is considered for themajority of MBC patients. Themedian
survival of patients with metastases whose disease has
become refractory to endocrine therapy or who have recep-
tor-negative tumours is 18–24 months. A major issue in treat-
ment selection is whether to use sequential single-agent
therapy or a combination regimen of two or more agents. Re-
sponse rates to initial therapy with anthracyclines (A), tax-
anes, capecitabine, vinorelbine, gemcitabine and platinum
salts range on average from 25% to 60%, with the median time
to progression averaging approximately 6 months. In general,
RRs diminish by half when the agents are used as second-
and third-line treatment, although there is a great variability
amongst trials. Although multidrug regimens of active agents
consistently show improved RRs that average approximately20% higher than those for single agents, single-agent sequen-
tial therapy is generally associated with less treatment-re-
lated toxicity, and numerous trials have shown no survival
advantage for combination therapy compared to single-agent
therapy. A Cochrane review and metanalysis published in
2005 comparing single versus combination CT in MBC showed
a statistically significant advantage for tumour response and
time to progression (TTP), but a modest improvement in over-
all survival (OS) and increased toxicities for multiagent treat-
ment. At the same time, another Cochrane paper showed that
taxane-containing regimens appear to increase OS, TTP and
overall response rate (ORR) with respect to non-taxane con-
taining ones.3,4 Fossati and colleagues in a metanalysis of sin-
gle-agent versus once used combinations CT found a
significant survival benefit for combination therapy that
translated into an absolute benefit in survival of 9% at 1 year,
5% at 2 years and 3% at 3 years.1 No individual trial included
in the analysis showed a significant survival benefit for com-
bination therapy, and no recent trials comparing single-agent
taxane regimens with multidrug regimens were included. It is
unclear whether patients in these trials had access to all the
agents used in the multidrug regimens. Most patients with
metastases are still best treated using a single-agent, sequen-
tial approach. There is no evidence that any specific sequence
of active agents is superior to another.
One clinical trial illustrates this principle.5 Sledge and col-
leagues randomly assigned 739 patients to either doxorubicin
alone, paclitaxel (P) alone or the combination of both agents.
The RR and TTP for the combination regimen (47% and 8.0
months, respectively) were significantly higher than those
for single-agent doxorubicin (36% and 5.8 months, respec-
tively) or P (34% and 6.0 months, respectively). However, sec-
ondary responses after changing over from P to doxorubicin
(22%) or from doxorubicin to P (20%) compensated for the
higher initial RRs and TTP for the combination regimen. Qual-
ity of life and survival time (median of 18.9 months for initial
doxorubicin treatment, 22.2 months for initial P and 22.0
months for P) were similar for all groups. A similar trial was
performed by Joensuu and colleagues, who compared weekly
epirubicin with cyclophosphamide, epirubicin and fluoroura-
cil; RRs, TTP and survival were similar in both groups,
whereas quality of life favoured the less toxic, weekly epirubi-
cin regimen.6 Moreover, unlike combination CT, treatment
with a single agent also allows the clinician to assess the ben-
efit of the specific agent being administered.
It appears that effective therapies, given either in combi-
nation or sequentially, can be valuable for treating advanced
BC. Single-agent, sequential CT treatment has the advantage
of isolating which of the agents is proving effective and of
simplifying decisions on CT dose optimisation for treat-
ment-related toxicity. For these reasons, this type of CT treat-
ment is preferable for most women receiving treatment for
advanced BC.
Choice of first-line CT depends on several considerations:
end-point of treatment (symptom palliation versus survival
prolongation), age, the wishes and comorbidities of the pa-
tient, treatment administered in adjuvant phase (A or not,
combination of A and taxanes), extent and symptom associ-
ated tumour burden, endocrine responsiveness and disease-
free interval from last administered CT.
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For A-naive patients, single agent (epi)doxorubicin or a combi-
nation of these agents with a taxane are appropriate choices.
Sequential pre-planned approaches with A and taxane7,8 ap-
pear less toxic and as active as combination schemes. Con-
versely combination of A and taxanes has not always been
shown to be superior to taxane-free schemes. In Bontenbal
andcolleaguesphases II–III trial, 216patientswere randomised
to doxorubicin and docetaxel (AD) or 5-fluorouracil-doxorubi-
cin and cyclophosphamide (FAC) combination.9 In this study,
combination with a taxane resulted in a significantly longer
TTP and OS and a higher ORR than a taxane-free one. In the
same manner, in Jassem et al.’s study11 which compared FAC
and AP in first-line setting, median TTP and OS were signifi-
cantly longer forAPcomparedwithFAC (TTP8.3monthsversus
6.2 months (P 0.034); OS 23.3 months versus 18.3 months (P
0.013)). Conversely at least four studies comparing A and tax-
anecombinationdidnotdemonstrateabenefit inOScompared
with A alone.10,12–14 Probably the differences noted in these tri-
als (other than population sample) are related to the different
activity of P and D schedules as reported later in this paper.
In conclusion preferred first-line chemotherapies include
sequential single agents (A, taxanes, pegylated lyposomial
doxorubicin, capecitabine, gemcitabine, vinorelbine, cisplati-
num or carboplatin) with combination CT (AD, AP, FAC, FEC,
AC, EC and CMF) preferred for rapidly evolving (visceral and
symptomatic) disease in patients with a good performance
status.4. A-pretreated patients
In this population various options exist for the medical oncol-
ogist treating advanced BC. Rechallenge with an anthracy-
cline, taxanes alone or in combination with other agents
(biological or not) or a non-taxane/non-anthracycline con-
taining CT. Initial studies incorporating taxanes showed that
D was superior in RR, TTP and OS to mitomycin and vinblas-
tine combination, offering an increased RR and TTP only com-
pared with methotrexate and 5-FU but showed comparable
efficacy to 5-FU + vinorelbine, even if less toxic.15–17
For A-pretreated, a well conducted, randomised trial com-
paring D and capecitabine with D alone in 511 patients would
appear to refute mono-CT strategy, because patients treated
with the combination regimen have statistically superior
RRs and disease-free survival and OS (14.5 months for the
combination and 11.5 months for single-agent D).18,19 How-
ever, in this trial only 17% patients were treated with capecit-
abine after tumour progression on D, and this group had a
superior OS compared to patients treated with the combina-
tion regimen. Randomised clinical trials in MBC that show
improved survival for a specific therapy should be reviewed
critically to ascertain that all patients had access to, or treat-
ment with, all active agents, whether as part of protocol ther-
apy or after the protocol therapy had been completed;
otherwise patients without access to other effective agents
are likely to have poorer survival.
Numerous clinical trials have investigated the activity and
efficacy of gemcitabine in association with taxanes. Thesestudies are of great importance, especially in view of the fact
that about two-thirds of patients with MBC have already re-
ceived adjuvant treatment with A and that, in these patients,
taxanesareusedas standard therapeutics. To compare the effi-
cacyand tolerability of the combination gemcitabine (1250 mg/
m2 days 1 and 8)–P (175 mg/m2 day 1) with that of P (175 mg/m2
day 1 q21) alone as first-line therapy in patients treatedwith A
in an adjuvant setting, an international multicentre study has
been carried out. The interim analysis of the trial, presented at
the 2004 ASCO Annual Meeting, showed a statistically signifi-
cant increase in RRs, TTP, and in particular, overall response
when gemcitabine was added to the taxane. The gemcita-
bine–P association represents a new therapeutic option as
first-line treatment of MBC patients pretreated with A.20
Bevacizumab (Avastin, Genentech) is a humanised mono-
clonal antibody directed against all isoforms of VEGF-A. Trial
E2100 compared P alone with P plus bevacizumab as initial
therapy for patients with MBC (40% and 17% of patients pre-
treated with an anthracycline and taxane in adjuvant phase).
From December 2001 to May 2004, a total of 722 patients were
enrolled. P plus bevacizumab significantly prolonged progres-
sion-free survival as comparedwith P alone (median, 11.8 ver-
sus 5.9 months; hazard ratio for progression, 0.60; P < 0.001)
and increased the objective RR (36.9% versus 21.2%,
P < 0.001). The overall survival rate, however, was similar in
the two groups (median, 26.7 versus 25.2 months; hazard ra-
tio, 0.88; P = 0.16).21
Another debate is which taxane is useful in first-line set-
ting. A phase III trial of one taxane compared to another
was published in 2005 by Jones and colleagues. D 100 mg/m2
and P 175 mg/m2 both day 1 every 21 d were compared in pa-
tients with advanced BC who had progressed after an A-con-
taining CT regimen. D was superior to P in terms of OS (15,4 vs
12, 7 months) TTP (5,7 vs 3,6 months). ORR was higher for D.
This study used a suboptimal P schedule. Infact weekly
administration seems superior to three-weekly P. In a recent
study including both Her-2 neu positive and negative ad-
vanced BC, weekly P was superior to a three-weekly adminis-
tration: RR (42% versus 29%, unadjusted odds ratio (OR) = 1.75;
P = .0004), TTP (median, 9 versus 5 months; adjusted
HR = 1.43; P < .0001), and survival (median, 24 versus 12
months; adjusted HR = 1.28; P = .0092). Neurotoxicity is a
treatment-limiting toxicity for weekly paclitaxel.22,23
To summarise a taxane (weekly P or three-weekly D) alone
or in combination with other cytotoxic or biological agents
represents a sound option for MBC (A-pretreated).5. A- and taxane refractory BC
For A and taxane pretreated patients the prognosis remains
poor even though other active agents (capecitabine, gemcita-
bine, platinum compounds, vinorelbine and lapatinib) can be
proposed. Capecitabine is an orally administered fluoropyr-
imidine that is metabolised to 5-fluorouracil by a series of
enzymatic steps. The efficacy of capecitabine in MBC has
been well documented in clinical trials that included patients
refractory to taxane therapy. Overall response rates have ran-
ged from 15% to 26%, with the median response duration and
survival ranging from 5.0 to 8.3 months and 10.1 to 15.2
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deoxycitidine that is enzymatically activated within cells to
inhibit DNA synthesis. Following A-based or taxane-based
CT, gemcitabine in doses of 800–1000 mg/m2 was well toler-
ated, and produced RRs ranging from 17% to 23%.
The vinca alkaloid, vinorelbine, is a fairly commonly used
treatment for BC that has shown promising results in the set-
ting of refractory advanced disease. Vinorelbine has been
evaluated in multiple phase II trials, with RR ranging from
16% to 34%. No phase III comparative information exists for
vinorelbine versus other single agents in the management
of patients with BC.24–32 Oral formulation of vinorelbine ap-
pears active in MBC, either in first-line or subsequent-line
therapy, alone or in combination with capecitabine, for exam-
ple.33–39
Carboplatin and cisplatin have also demonstrated good
activity in combination with other agents (especially
taxanes and gemcitabine) in pretreated patients (RR range
29–62%).40–45
In a large randomised trial of BC patients who had been
previously treated with A and taxanes, Miller and col-
leagues.46 reported a better RR with bevacizumab plus cape-
citabine compared with capecitabine monotherapy; but
survival rates did not differ in the two treatment groups.
Advancements in cell biology have expanded our under-
standing of fundamental molecular pathways, opening the
way for new and innovative treatments in MBC patients al-
ready treated with hormone, A and taxane therapies. In the
near future ixabepilone, nanoparticle P, vinflunine and novel
biological agents will expand treatment option in this setting.
Both patients and clinicians have every reason to be
optimistic.6. Duration of CT
The length of time patients with stable disease should under-
go CT remains a major issue, especially for those who have
high-quality responses or disease stabilisation but major
treatment-related toxicity. Contrary to the perception of
many, quality of life is not adversely affected and may even
be improved in many patients actively receiving CT. Coates
and colleagues compared continuous therapy with AC or
CMF with intermittent therapy using three cycles of the same
regimen with reinstitution of therapy at the time of disease
progression.47 In this trial, patients receiving continuous ther-
apy had superior RRs, TTP and quality-of-life scores, but no
improvement in survival. A similar trial by the Piedmont
Oncology Association randomly assigned patients who had
responding or stable disease after six cycles of CAF to either
CMF or observation, followed by reinstatement of CMF at dis-
ease progression.48 Although TTP was more than twice as
long for patients on continuous therapy than for those with
interrupted treatment (9.4 versus 3.2 months, respectively),
OS was similar. Falkson and colleagues randomly assigned
141 patients whose measurable disease showed a complete
response after six cycles of CAF to receive either chemo-hor-
monal therapy or undergo observation.49 Time to disease pro-
gression was 19 months for patients given chemo-hormonal
therapy and 8 months for patients under observation; OSwas similar. These data suggest that a ‘drug holiday’ is asso-
ciated with a shorter TTP but no adverse effect on survival.
Recently, new drugs have entered clinical trials to compare
different durations of treatments. Gennari and colleagues
treated patients with A and P combination followed by P or
no therapy in responding or in stable disease patients. Median
survival and TTP did not differ in the two groups.50 Oncolo-
gists should share these data with patients, as some patients
may wish a ‘drug holiday’ whereas others, especially those
with substantial tumour-related symptoms before treatment,
may wish to continue their therapy. In addition, these data
support newer randomised trial designs that, after remission
induction with standard treatment, compare new agents with
observation, or new agents with established agents. Such de-
signs use TTP as the major treatment end-point, and are
especially suitable for the investigation of biologic agents.7. Hormonal therapy for endocrine responsive
(HER-2 negative) advanced BC
Women with recurrent or metastatic disease characterised by
tumours that are ER and/or PgR positive are appropriate can-
didates for initial endocrine therapy, especially if the disease
is confined to bone and or lymphnodes. Choice of first-line
hormonal therapy depends on the initial adjuvant treatment,
tamoxifen or aromatase inhibitor (AI) based. If the patient
had been pretreated with adjuvant antioestrogen therapy or
relapses during the same treatment (for example tamoxifen),
first-line therapy with an AI (anastrozole or letrozole) is supe-
rior to megestrole acetate.51,52
For postmenopausal women who are antioestrogen naive
or have relapsed more than 1 year from previous antioestro-
gen therapy, the AI therapy appears to have a minimal but
superior outcome compared with tamoxifen. So appropriate
first-line therapies in this setting are antioestrogens and
AIs.53–56
Fulvestrant is a pure ER antagonist or down-regulator
without agonist properties that has been approved as a sec-
ond-line therapy following tamoxifen in postmenopausal wo-
men with advanced BC. In a randomised, double-blind,
parallel-group, multinational study comparing 250 mg fulve-
strant given as an intramuscular monthly injection or daily
tamoxifen (n = 587) as a first-line therapy for advanced BC in
postmenopausal women, no significant differences were seen
between groups for TTP or RR at a median follow-up of 14.5
months.57 Treatment with fulvestrant in patients whose dis-
ease progressed after treatment with tamoxifen resulted in
similar TTP and RR compared with anastrozole,58 providing
another treatment option for postmenopausal women with
hormonal receptor positive advanced BC. For premenopausal
women standard first-line endocrine therapy (if antioestrogen
naive) is a course of an antioestrogen with or without chem-
ical or radio/surgical ovarian ablation. In the setting of antio-
estrogen pretreatment, after inducing ovarian ablation, the
patient can be treated with endocrine therapy as for post-
menopausal women.
Many women with hormone responsive BC benefit from
sequential use of endocrine therapies at the time of disease
progression, unless visceral crisis appears. Recent National
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up to three hormonal therapy lines in the presence of endo-
crine sensitive disease. The same guidelines recommend
the use of an AI in postmenopausal women with recurrent
BC who had received antioestrogen treatment within the past
12 months.59 Another option for second-line endocrine treat-
ment is fulvestrant, which has been shown to be as effective
as anastrozole in patients whose disease progressed during
tamoxifen treatment (see above). Several studies have evalu-
ated sequential hormone therapy and found small but consis-
tent response regardless of the order in which therapy was
administered.60–62 The recently presented phase III EFECT
trial evaluated sequential therapy with an AI compared to ful-
vestrant.63 Six hundred and ninety-three postmenopausal
women with advanced endocrine responsive BC who had
recurrent or progressive disease following treatment with a
non-steroidal AI were randomised to receive either exemes-
tane or a modified loading dose of fulvestrant. Median TTP
was 3.7 months in both groups; RR and rate of clinical benefit
were also identical. The median duration of response was
quite long, ranging from 9.8 to 13.5 months and CB was seen
in up to 29% patients with visceral dominant disease, regard-
less of prior response to non-steroidal AI. Again, this indi-
cates that patients with hormone-sensitive BC benefit from
sequential administration of available hormone agents. To
summarise AI and fulvestrant as first- and second-line treat-
ments (in case of tamoxifen adjuvant treatment) and fulve-
strant with subsequent AI (if the patient has been treated
with an AI in the adjuvant phase) represent standard options
for endocrine responsive, postmenopausal patients. For pre-
menopausal patients, treated with adjuvant tamoxifen (alone
or combined with LHRH analogues) options are represented
by an AI combined with LHRH analogues and later by medr-
oxy progesterone acetate or megestrole acetate.8. Conclusion
MBC has to be considered a chronic disease, and the oncolo-
gist now has multiple treatment options to prolong disease
control. Standard first-line chemotherapy consists of anthra-
cyclines plus or minus a taxane depending on the end-point
of treatment. A recently published individual patient’s data
metanalysis confirms this concept. Taxane-based combina-
tions were significantly better than A-based combinations in
terms of RR and progression-free survival, but not in terms
of survival. Polychemotherapy remains indicated if the end-
point is cytoreduction of high tumour burden. Single agent
taxane and single agent A are equivalent in terms of RR and
OS and are prescribed if the end-point is the control of disease
and prolongation of survival.64 First-line AI (steroidal or non-
steroidal) and subsequent fulvestrant or an AI of the opposite
class is an appropriate sequence for the treatment of ad-
vanced endocrine responsive disease.
Today systemic therapy is at the cornerstone of treatment
in the advanced setting. Prognosis remains severe (from
months to a few years) even if some long-term survivors ex-
ist, in particular those who achieve long-term (complete)
remission with standard chemotherapy regimens.65,66 Surgi-
cal resection of secondary or primary sites in stage IV disease(lung, liver, brain, primary tumours with synchronous indo-
lent metastasis) can be offered in selected cases, obtaining
prolongation of survival and/or local control.67–72
Concern regarding critical aspects remain. In particular
what is the choice of first-line therapy in oligometastatic
and paucisymptomatic, endocrine responsive disease? Is a
poly-CT better than a mono-CT in a rapidly progressing dis-
ease? Is there a role for a maintenance therapy after obtaining
a clinical benefit, or after the introduction of a more frequent
and convenient schedule of administration (metronomic
therapy)? Finally what is the role of biological agents in com-
bination with chemotherapy or hormonal therapy? Interest-
ing areas of research represent the so-called triple negative
BC (non-expressing hormonal receptor and Her2-neu). In this
setting high dose therapy, platinum salts, ixabepilone (recent
interesting data had been presented at 2007 SABCS by Rugo
et al.73) and target agents are in a phase of intense study.
The benefit of an angiogenetic therapy with the scope of
blocking certain critical pathways for tumoural cells (for
example angiogenesis) has recently been confirmed in at
least two phase III trials comparing CTwith or without bev-
acizumab. Combination of endocrine agents with target ther-
apies with the scope of overcoming primary and secondary
resistance is emerging as interesting solution. The inefficacy
of A in Her2-neu disease, at least in adjuvant setting, seems
to delineate a possible new strategy: from more toxic CT
drugs to more specific, target oriented molecules. The near
future will tell us if this scenario will become standard in clin-
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